Journal
TRENDS IN CANCER
Volume 6, Issue 11, Pages 974-984Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2020.05.011
Keywords
-
Categories
Funding
- Bundesministerium fur Bildung und Forschung [02NUK032, 02NUK035B]
Ask authors/readers for more resources
Molecular-targeted therapies and treatment stratification based on molecular biomarkers have rapidly gained momentum in the therapeutic spectrum for patients with prostate cancer, particularly those with aggressive disease. DNA damage repair (DDR) pathways are commonly impaired in prostate cancer. Recent studies have detailed mechanisms interconnecting the DDR with the androgen receptor (AR) signaling pathway as well as its interplay with the immune response. The prominent role of DDR deficiency in prostate cancer development and treatment response encourages innovative strategies for the detection of DDR deficiency in individual tumors. In this review, we describe recent preclinical and early clinical data on the exploitation of DDR defects as predictive biomarkers and also as molecular therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available